Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is developing a platform that will allow consumers to program cells with the same ease as computers. The company's platform is market agnostic, allowing biotechnology applications in various industries, including food and agriculture, industrial chemicals, and medicines.
Key Highlights:
- Due to the progress of programs with existing and new clients, as well as the introduction of biosecurity products, the firm recorded a substantial increase in total revenues to USD 77.61 million in Q3FY21 (ending September 30, 2021) from USD 13.30 million in Q3FY20.
- However, its net losses widened to USD 102.41 million in Q3FY21 from USD 26.13 million in Q3FY20.
- The company's accumulated deficit has increased to USD 697.27 million as of September 30, 2021, from USD 467.88 million as of September 30, 2020.
- DNA has been operated at a lower gross margin of 71.3% in Q3FY21 compared to the industry median of 85.3%.
- As a loss-making enterprise, the company has generated negative EBITDA, operating, and net margins compared to positive industry margins.
- The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 35.93, indicating a bearish trend.
- Stock is leaning towards the lower band of the 52-week range of USD 4.34 to USD 15.86.
- Its stock price fell 64.54% and 52.06% in the past three and six months, respectively.
One-Year Technical Price Chart (as of February 18, 2022; 11:23 AM ET). Analysis by Kalkine Group
Conclusion: Considering the substantial increase in losses, weak margins, unclear outlook, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 4.77, down 3.44%, as of February 18, 2022, at 11:23 AM ET.
*The reference data in this report has been partly sourced from REFINITIV.
Regis Corporation
Regis Corporation (NYSE: RGS) is a beauty salon company that owns, franchises, and operates salons across North America and the United Kingdom. The outlets offer mass-market salon products and services, such as haircutting, styling, and hair coloring. The great majority of its salons in North America are located in strip malls, shopping centers, and Wal-Mart stores, and cater to budget-conscious clientele.
Key Highlights:
- The company reported a 32.65% decline in total revenues to USD 70.26 million in Q2FY22 (ended December 31, 2021) from USD 104.32 million in Q2FY21, due to a deterioration in company-owned salon sales.
- The company witnessed a decline in net losses to USD 4.93 million in Q2FY22 from USD 32.88 million in Q2FY21.
- As of September 30, 2021, its debt/equity ratio was 5.07x, compared to the industry median of 0.40x, indicating a solvency risk to its balance sheet.
- Stock is currently trading between its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 57.74, indicating an overbought zone.
- Stock is leaning towards the lower band of the 52-week range of USD 1.30 to USD 13.92.
- The stock is highly volatile as it has shown a significant drop of 82.09% in the past twelve months.
Three-Year Technical Price Chart (as of February 18, 2022; 11:28 AM ET). Analysis by Kalkine Group
Conclusion: Considering the volatile nature of the stock, fall over in topline, highly leveraged balance sheet, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 1.845, down 4.90%, as of February 18, 2022, at 11:28 AM ET.
*The reference data in this report has been partly sourced from REFINITIV.
Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical-stage pharmaceutical business focused on developing therapeutic candidates for the treatment of highly resistant malignancies and viruses. Annamycin, the WP1066 Portfolio, and the WP1122 Portfolio are the company's three primary technologies, which feature a total of five therapeutic candidates, three of which have shown human action in clinical trials.
Key Highlights:
- The company is yet to report any revenue from its operations.
- The company's net losses widened to USD 4.38 million in Q3FY21 from USD 3.40 million in Q3FY20. Since its beginning, the company has incurred net losses, and the prospects aren't looking promising due to a lack of commercial revenues.
- The company's accumulated deficit has increased to USD 69.98 million as of September 30, 2021, from USD 56.92 million as of September 30, 2020.
- The company is constantly issuing common stock and warrants, diluting existing shareholders' holdings and reducing their ownership in the company.
- The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 29.39, indicating a bearish trend.
- Stock is leaning towards the lower band of the 52-week range of USD 1.31 to USD 5.03.
- Its stock price fell 39.09% and 51.62% in the past three and six months, respectively.
Three-Year Technical Price Chart (as of February 18, 2022; 11:22 AM ET). Analysis by Kalkine Group
Conclusion: Considering the substantial increase in losses, lack of clarity in topline, bleak outlook, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 1.34, down 3.60%, as of February 18, 2022, at 11:22 AM ET.
*The reference data in this report has been partly sourced from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.